Zhu Shengjie, Shao Bin, Hao Yaoyao, Li Zongxian, Liu Houqiang, Li Hong, Wang Ming, Wang Kai
Department of Oncology, Wendeng Central Hospital of Weihai City, Weihai, Shandong, China.
Department of Radiology, Wendeng Central Hospital of Weihai City, Weihai, Shandong, China.
Cancer Biomark. 2015;15(1):89-97. doi: 10.3233/CBM-140441.
Ghrelin was associated with several of cancers. The conflict results of SNPs with GHRL and GHSR gene were demonstrated in different studies. Thus, this meta-analysis is to evaluate the associations.
Systematic literature search was done on PubMed database up to October 2013. We used odds ratios (ORs) with 95% confidence intervals (CIs) to assess the strength of the association by a fixed-effect model and a random-effect model.
A total of 7 studies, which included 3 studies for breast cancer, 2 for colorectal cancer, 1 for hepatocellular carcinoma, 1 for esophageal cancer and 1 for Non-Hodgkin lymphoma. When analyzed all the GHRL SNPs with all kinds of cancers, there was significantly difference with cancer patients compared with controls (Recessive model: OR 0.938, 95% CI 0.890-0.989, p=0.017), while no significant difference was existed in the additive model (OR 0.9903, 95% CI 0.957-1.024, p=0.558) and dominant model (OR 1.014, 95% CI 0.970-1.061, p=0.536). When analyzed all the GHSR SNPs with all kinds of cancers, no significant difference was observed.
Our results suggest that the SNP with GHRL and GHSR might be weaker association with cancer risk, especially with breast cancer risk.
生长素释放肽与多种癌症相关。不同研究显示了生长激素释放肽（GHRL）基因和生长激素促分泌素受体（GHSR）基因单核苷酸多态性（SNPs）的矛盾结果。因此，本荟萃分析旨在评估这些关联。
截至2013年10月，在PubMed数据库上进行了系统的文献检索。我们使用比值比（ORs）及95%置信区间（CIs），通过固定效应模型和随机效应模型评估关联强度。
共有7项研究，其中3项针对乳腺癌，2项针对结直肠癌，1项针对肝细胞癌，1项针对食管癌，1项针对非霍奇金淋巴瘤。当分析所有癌症患者的GHRL SNPs时，与对照组相比有显著差异（隐性模型：OR 0.938，95%CI 0.890 - 0.989，p = 0.017），而在加性模型（OR 0.9903，95%CI 0.957 - 1.024，p = 0.558）和显性模型（OR 1.014，95%CI 0.970 - 1.061，p = 0.536）中无显著差异。当分析所有癌症患者的GHSR SNPs时，未观察到显著差异。
我们的结果表明，GHRL和GHSR的SNP与癌症风险，尤其是乳腺癌风险的关联可能较弱。
